Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase
Open Access
- 2 September 2024
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (10) , 2731-2744
Abstract
Background: Neuromyelitis optica spectrum disorder (NMOSD) is an anti‐aquaporin 4 (anti‐AQP4) autoantibodies‐mediated idiopathic inflammatory demyelinating disease of the central nervous system. While intravenous pulse methylprednisolone (IVMP) is the recommended initial treatment option for acute onset NMOSD, its therapeutic mechanism remains unclear. We hypothesized that IVMP would reduce the expression of pro‐inflammatory factors and increase the resolution of inflammation in patients with NMOSD.Methods: Mendelian randomization (MR) analysis was used to screen meaningful inflammatory and resolution factors for inclusion. Three MR methods with inverse variance weighting (IVW) were primarily used to identify positive results. Interleukin (IL)‐10, IL‐1β, IL‐6, C‐X‐C motif chemokine ligand 12 (CXCL12), and tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) were screened from 41 inflammatory factors, and resolvin D1 (RvD1), maresin 1 (MaR1), and lipoxin A4 (LXA4) were screened from 6 resolution markers for inclusion. Subsequently, 12 patients with NMOSD were enrolled and treated with IVMP. Serum levels of the aforementioned inflammatory and resolution markers were measured by enzyme‐linked immunosorbent assay before and after IVMP treatment.Results: High levels of TRAIL, CXCL12, and IL‐1β were associated with an increased risk of NMOSD (TRAIL: odds ratio [OR], 1.582; 95% confidence interval [CI], 1.003–2.495; CXCL12: OR, 3.610; 95% CI, 1.011–12.889; IL‐1β: OR, 4.500; 95% CI, 1.129–17.927). High levels of RvD1, MaR1, and LXA4 were associated with a reduced risk of NMOSD (RvD1: OR, 0.725; 95% CI, 0.538–0.976; MaR1: OR, 0.985; 95% CI, 0.970–0.999; LXA4: OR, 0.849; 95% CI, 0.727–0.993). Among patients with NMOSD, serum levels of IL‐6, CXCL12, and TRAIL significantly decreased following IVMP treatment, compared with pretreatment levels, while levels of IL‐1β, LXA4, and MaR1 significantly increased after IVMP treatment (p < 0.05). A significant positive correlation was observed between CXCL12 levels and Expanded Disability Status Scale (EDSS) scores (r = 0.451, p < 0.05).Conclusion: Several systemic inflammatory regulators associated with the pathogenesis of NMOSD were identified. The protective roles of LXA4 and MaR1 may be indispensable components of glucocorticoid treatment. Therefore, the use of resolution markers may be a potential strategy for improving central nervous system injury in individuals with NMOSD.Keywords
Funding Information
- Department of Science and Technology of Jilin Province (YDZJ202301ZYTS028, 20240402014GH)
This publication has 58 references indexed in Scilit:
- Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian RandomizationJAMA, 2021
- Lipoxin A4 protects primary spinal cord neurons from Erastin‐induced ferroptosis by activating the Akt/Nrf2/HO‐1 signaling pathwayFEBS Open Bio, 2021
- Lipoxin A4 protects against spinal cord injury via regulating Akt/nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 signalingBiomedicine & Pharmacotherapy, 2018
- Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth FactorsThe American Journal of Human Genetics, 2017
- Omega-3 fatty acids as an adjunct for periodontal therapy—a reviewClinical Oral Investigations, 2016
- Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment coursesAnnals of Neurology, 2015
- Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized DataGenetic Epidemiology, 2013
- Aquaporin 4‐specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporterAnnals of Neurology, 2012
- Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammationJournal of Molecular Medicine, 2009
- Neuromyelitis optica: Diagnosis, pathogenesis, and treatmentCurrent Neurology and Neuroscience Reports, 2008